Dabigatran in atrial fibrillation

4th April 2012 by Louise Hudman

This guideline lays out the criteria for the use of Dabigatran, a thrombin inhibitor.

It can be considered as an alternative to warfarin in non-valvular AF if at least one of the following applies:

  • Previous CVA / TIA / systemic embolism
  • LV ejection fraction < 40%
  • Heart Failure NYHA II or above
  • ≥ 75
  • ≥ 65 + DM or coronary artery disease or hypertension

It is much more expensive than warfarin, though at higher doses is more effective at reducing stroke. Its major benefits are in not having so many food and drug interactions and not needing monitoring. We will need to wait to see how this will be used locally.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I was delighted to have been invited to join GP locum chambers. I enjoy great peer support from my colleagues via our monthly meetings, which has been helpful to me discussing some specific things that arise with GP locum working.

I have found LocumDeck really straightforward to use and immensely helpful; in particular invoicing and the pension forms A and B has cut down my admin time dramatically, which I’m pleased about. The support from NASGP's membership support manager, is excellent, friendly and knowledgeable.

NASGP membership brings with it a host of benefits, including a range of excellent materials to draw on for support and learning. I would recommend NASGP chambers to anyone working or thinking of working as a GP locum."

Dr Chloe Evans

Dr Chloe Evans

See the full list of features within our NASGP membership plans

Membership